Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

BCMA inhibitor

DRUG CLASS:

BCMA inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	teclistamab Sensitive: A1 - Approval teclistamab Sensitive : A1	teclistamab Sensitive: A1 - Approval teclistamab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	elranatamab Sensitive: A1 - Approval elranatamab Sensitive : A1	elranatamab Sensitive: A1 - Approval elranatamab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	HPN-217 Sensitive: B - Late Trials HPN-217 Sensitive : B	HPN-217 Sensitive: B - Late Trials HPN-217 Sensitive : B
TNFRSF17-L	Multiple Myeloma	TNFRSF17-L	Multiple Myeloma	AMG 701 Sensitive: C3 – Early Trials AMG 701 Sensitive : C3	AMG 701 Sensitive: C3 – Early Trials AMG 701 Sensitive : C3
IL6-L	Multiple Myeloma	IL6-L	Multiple Myeloma	elranatamab Sensitive: C3 – Early Trials elranatamab Sensitive : C3	elranatamab Sensitive: C3 – Early Trials elranatamab Sensitive : C3
TNFRSF17 amplification	Multiple Myeloma	TNFRSF17 amplification	Multiple Myeloma	elranatamab Resistant: C3 – Early Trials elranatamab Resistant : C3	elranatamab Resistant: C3 – Early Trials elranatamab Resistant : C3
CCL3-L	Multiple Myeloma	CCL3-L	Multiple Myeloma	elranatamab Sensitive: C3 – Early Trials elranatamab Sensitive : C3	elranatamab Sensitive: C3 – Early Trials elranatamab Sensitive : C3
IL17C-L	Multiple Myeloma	IL17C-L	Multiple Myeloma	elranatamab Sensitive: C3 – Early Trials elranatamab Sensitive : C3	elranatamab Sensitive: C3 – Early Trials elranatamab Sensitive : C3
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	elranatamab Sensitive: C3 – Early Trials elranatamab Sensitive : C3	elranatamab Sensitive: C3 – Early Trials elranatamab Sensitive : C3
Chr t(14;16)	Multiple Myeloma	Chr t(14;16)	Multiple Myeloma	elranatamab Sensitive: C3 – Early Trials elranatamab Sensitive : C3	elranatamab Sensitive: C3 – Early Trials elranatamab Sensitive : C3
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	elranatamab Sensitive: C3 – Early Trials elranatamab Sensitive : C3	elranatamab Sensitive: C3 – Early Trials elranatamab Sensitive : C3
TNFRSF17 positive	Multiple Myeloma	TNFRSF17 positive	Multiple Myeloma	teclistamab Sensitive: D – Preclinical teclistamab Sensitive : D	teclistamab Sensitive: D – Preclinical teclistamab Sensitive : D
TNFRSF17 underexpression	Multiple Myeloma	TNFRSF17 underexpression	Multiple Myeloma	CTX-8573 Sensitive: D – Preclinical CTX-8573 Sensitive : D	CTX-8573 Sensitive: D – Preclinical CTX-8573 Sensitive : D
TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	CC-93269 + CC-220 Sensitive: D – Preclinical CC-93269 + CC-220 Sensitive : D	CC-93269 + CC-220 Sensitive: D – Preclinical CC-93269 + CC-220 Sensitive : D
TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	CC-93269 + CC-92480 Sensitive: D – Preclinical CC-93269 + CC-92480 Sensitive : D	CC-93269 + CC-92480 Sensitive: D – Preclinical CC-93269 + CC-92480 Sensitive : D